Reckitt Benckiser to unveil £105 R&D site in Hull by end of June
pharmafile | April 11, 2019 | News story | Manufacturing and Production | Hull, R&D, Reckitt Benckiser, UK, pharma
Reckitt Benckiser (RB) has announced that its £105 million research and development facility in the UK city of Hull – the company’s largest-ever single investment – is to open before the end of June this year.
The new prospective date was set after the original unveiling, planned by the end of 2018, was postponed.
The site at Dansom Lane was touted as a major step in pushing UK to become a “world leader in science and innovation” as then-Chancellor George Osborne put it upon its original reveal in 2014.
“The main thing for us has been getting the quality right. These are health care products which we will be developing in the centre, so it is critical everything is correct,” commented Dr Bruce Charlesworth, Research and Development Site Lead at RB. “We are in the final stages, I think it is fair to say, and it is really just about putting the finishing touches on everything before we move in.”
Included within the site is a new laboratory suite and data procurement facilities, in addition to one of Europe’s largest stability testing suites.
“We have got to keep stock of the big products in all the shops, and previously when we have been doing testing there has been the risk of stocking problems,” Dr Charlesworth added. “The centre will also enable us to be more connected to our consumers. They will be able to see, touch and smell products in a way they haven’t been able to before.”
The investment marks the latest point in RB’s relationship with Hull, which began in 1840 when the company rented a starch mill in the city.
Matt Fellows
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Addenbrooke’s hospital offers first self-service digital eye test
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing …
ANGLE’s Parsortix system used in new cancer biology research
ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour …
